Response to Comment on Paolisso et al. Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care 2021;44:2158–2161

Pasquale Paolisso,Luca Bergamaschi,Pietro Rambaldi,Gianluca Gatta,Alberto Foà,Francesco Angeli,Michele Fabrizio,Gianni Casella,Michelangela Barbieri,Nazzareno Galiè,Raffaele Marfella,Carmine Pizzi,Celestino Sardu
DOI: https://doi.org/10.2337/dci21-0042
2021-10-18
Diabetes Care
Abstract:In a letter in this issue of Diabetes Care, Madias suggests that norepinephrine, as mediator of admission hyperglycemia (AH), is an index of increased underlying sympathetic overactivity and/or diabetes comorbidity in patients with takotsubo syndrome (TTS) (1). Indeed, the 28 patients with AH versus the 48 patients without AH had a higher prevalence of diabetes (39.3% vs. 14.6%) (1,2). Notably, AH was a predictor of long-term prognosis in TTS patients (2). Moreover, the patients with AH showed lower left ventricular ejection fraction on admission and discharge and higher B-type natriuretic peptide and inflammatory markers, with the glucose values correlating with serum norepinephrine levels (2). Intriguingly, of the 30 patients who underwent a 123I-MIBG cardiac scintigraphy, patients with AH showed lower late heart-to-mediastinum ratio values at a follow-up of 12 and 24 months than those without AH (2). Furthermore, the patients with AH had higher rates of heart failure (HF) and all-cause mortality after 24 months than those without AH, with tumor necrosis factor-α and serum norepinephrine being independent predictors of HF (2). Thereafter, the acute TTS event appears to link AH to HF via overinflammation and oversympathetic system activation (2).
endocrinology & metabolism
What problem does this paper attempt to address?